Status:
RECRUITING
Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection
Lead Sponsor:
Tanta University
Conditions:
Potassium-Competitive Acid Blocker
Proton Pump Inhibitor
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patient...
Detailed Description
Helicobacter pylori (H. pylori) is a spiral-shaped, Gram-negative bacterium that colonizes the stomach lining and is considered one of the most prevalent chronic infections globally. Bismuth-based qu...
Eligibility Criteria
Inclusion
- Adults aged ≥18 years.
- Both sexes.
- Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT).
- No prior eradication therapy.
Exclusion
- Prior Helicobacter pylori treatment.
- Use of antibiotics, proton pump inhibitor, or bismuth in the prior 4 weeks.
- Gastric surgery history.
- Major organ failure.
- Pregnancy or lactation.
- Known allergy to study drugs.
Key Trial Info
Start Date :
September 11 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT07165444
Start Date
September 11 2025
End Date
February 1 2026
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527